Horizon Pharma, Inc.

-$0.77 (-1.3%)
Closing price July 10, 2020
24/7 Wall St. has collected several big FDA decisions and mid- to late-stage trials that should be coming up in November and December.
If we look at what Horizon is paying, it doesn’t necessarily add up, using the numbers from this year, but if we look at more data the picture becomes clearer.
Horizon Pharma reported better-than-expected first-quarter financial results before the markets opened on Monday.
A new Jefferies research report focuses on some biotech and specialty pharmaceutical stocks that have had some headline and clinical issues muddy the waters.
This last week may have been short and light on investing interest in the United States. After all, millions of passengers flying out or driving out on Wednesday, then eating more turkey than can...
Stocks were indicated lower on Monday, but that is after the best week for stocks in quite some time. This is a thinner week for liquidity and analyst calls are likely to dry up on Tuesday or...
The biotech companies 24/7 Wall St. has picked stood out from the rest with incredible gains or losses over the course of the past week.
In a fresh report, Janney Capital Markets has said that bad news for Horizon Pharma is creating a buying opportunity in DepoMed.
Shots were fired again on the Horizon Pharma and DepoMed merger front. However it was DepoMed this time pushing back.
Horizon Pharma announced Monday morning that it expects its second-quarter financial results will be of record proportion.
Horizon Pharma has gone hostile in its attempt to take over DepoMed. These companies have been in talks since March, but an agreement was never reached.
It has been a zigzagging year so far for the major indexes. Here is a quick look of the five biggest gainers and losers on the major exchanges since January 1.
Thursday's top analyst upgrades, downgrades and initiations include Chesapeake Energy, Rite Aid, Harley-Davidson, Toll Brothers and Transocean.
Friday's top analyst upgrades, downgrades and initiations include BP, Netflix, Otonomy, Salesforce.com, Total and VeriFone Systems.
Friday's top analyst upgrades, downgrades and initiations include Apple, Clovis Oncology, Deere, JC Penney, Wynn Resorts and Yum! Brands.